About us
Onco Biomedical Technology(Suzhou). CO.,Ltd is a biotechnology company based in Suzhou, Jiangsu Province China in November,2010.
Our company is a high-tech biomedical joint venture devoted to conducts research and development on new technologies of solid tumor diagnose and treatment. Our total investment is 18 million US dollars, and the registered capital is 7.43216422 million US dollars.
At the first stage, we force on the new-style non-invasive diagnostic kit of prostatitis which is based on urine sample. We also provide advanced diagnostic technology for early-stage diagnosis of a variety of solid cancers, like prostatic cancer, lung cancer, esophagus cancer, pancreatic cancer, breast cancer, ovarian cancer, etc which give deeper insight on the cancer early detection. At the same time, our another key tool is the molecular detection of cancer genetic aberrance in the incidence of cancer, which will highly improve prognosis accurate rate of cancer suffers. In this way, we can improve the effectiveness and the life quality by using the best individual treatment options. We are determined to expand clinical acceptance of these detection in 5 years, improve the commercial value of screening technology for cancer specific protein, and finally build a Chinese-style cancer testing center in Suzhou.
Onco technical team is composed by foreign and native experts in cancer research leading by Dr.Qun Lu, the management team is a team with administrative experience of group company leading by general manager Ze Qian. With the development of our company, we plan to introduce 4-5 talents with doctor degree in certain major, and about 40 research staff with College degree to form a group of 50 people for R &D, sales and technical service.
Our aim: benefits of cancer suffers oriented，apply production for clinical use, earlier diagnosis，earlier treatment，prevent malignant metastasis，improve the patients live quality.
